Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Featured trial
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Children and Adolescents >6 to

The main purpose of this study is to learn whether the study drug, rimegepant, is well tolerated and safe for the prevention of migraine compared to placebo in children and adolescents between the ages of 6 and 17 years. Enrollment starts with the 12 to 17 year old group. The …

  • 0 views
  • 19 Jan, 2023
  • 1 location
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine (PROSPECT-2)

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

  • 0 views
  • 21 Oct, 2022
  • 20 locations
Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age.

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).

  • 6 views
  • 25 Oct, 2022
  • 96 locations
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in …

body mass index
preventive medication
headache
migraine in children
  • 16 views
  • 04 Oct, 2022
  • 54 locations
A Phase 3, Randomized, Doubleblind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic

episodic migraine
migraine in children
  • 0 views
  • 21 Oct, 2022
  • 33 locations
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2 (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study

migraine in children
ly573144
lasmiditan
acute treatment
  • 176 views
  • 24 Oct, 2022
  • 172 locations
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)

sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate long term safety and tolerability of ubrogepant in the acute treatment of migraine in children and

nausea
acute treatment
severe headache
migraine in children
headache
  • 19 views
  • 29 Oct, 2022
  • 75 locations
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)

sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and

nausea
acute treatment
severe headache
migraine in children
headache
  • 17 views
  • 21 Oct, 2022
  • 75 locations
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.

migraine in children
  • 0 views
  • 09 May, 2022
  • 11 locations
A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

The purpose of the study is to investigate how the body absorbs, distributes, and get rid of eptinezumab when given directly into a vein.

headache
  • 54 views
  • 04 Oct, 2022
  • 18 locations